GenScript is best known for its gene synthesis capabilities, which we estimate is more than half of the life science services and products segment. In 2014, GenScript was the leader in gene synthesis, ...

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech ...

R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...

PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research ...

In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...

The MarketWatch News Department was not involved in the creation of this content. Panel discussions brought to life important insights into how AI could change the face of biopharma drug discovery in ...

PISCATAWAY, N.J., April 23, 2024 /PRNewswire/ -- GenScript Biotech Corporation (GenScript), one of the world's leading providers of life-science research tools and services, and Multiply Labs, a ...

GenScript continues to build on its fast and dependable in vitro transcription RNA synthesis service, offering a new self-amplifying RNA format that enhances the potency and efficacy of vaccines, ...

PISCATAWAY, N.J., July 31, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG ...

Genscript Biotech ( (HK:1548)) just unveiled an update. Genscript Biotech Corporation announced the financial results for the third quarter of 2025 for its associate, Legend Biotech Corporation, which ...

Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...